Trial Profile
A prospective cohort study to evaluate the nucleoside reverse transcriptase inhibitor in first-line antiretroviral therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Stavudine (Primary) ; Tenofovir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 09 Dec 2015 New trial record